Reich Kristian

SEC source: 0001213900-26-082804 · ownership.xml · nonDerivative · entry 1

Reich Kristian · CIK 0001920553 · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Indirect · See footnote.

Disclosed balance after: 2,711,198

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 10, 2026.

F2 · ownership.nature: Represents the ordinary shares of the Issuer owned by JeruCON Beratungsgesellschaft mbH. Dr. Reich directly (whether through ownership or position) or indirectly through one or more intermediaries, may be deemed for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, to be the indirect beneficial owner of the ordinary shares owned by JeruCON Beratungsgesellschaft mbH.

SEC source: 0001213900-26-080869 · ownership.xml · nonDerivative · entry 2

Reich Kristian · CIK 0001920553 · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Indirect · See footnote.

Disclosed balance after: 2,712,298

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 10, 2026.

F3 · ownership.nature: Represents the ordinary shares of the Issuer owned by JeruCON Beratungsgesellschaft mbH. Dr. Reich directly (whether through ownership or position) or indirectly through one or more intermediaries, may be deemed for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, to be the indirect beneficial owner of the ordinary shares owned by JeruCON Beratungsgesellschaft mbH.

SEC source: 0001213900-26-080869 · ownership.xml · nonDerivative · entry 1

Reich Kristian · CIK 0001920553 · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Indirect · See footnote.

Disclosed balance after: 2,714,746

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 10, 2026.

F2 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $20.00 to $20.06. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

F3 · ownership.nature: Represents the ordinary shares of the Issuer owned by JeruCON Beratungsgesellschaft mbH. Dr. Reich directly (whether through ownership or position) or indirectly through one or more intermediaries, may be deemed for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, to be the indirect beneficial owner of the ordinary shares owned by JeruCON Beratungsgesellschaft mbH.

SEC source: 0001213900-26-080133 · ownership.xml · nonDerivative · entry 1

Reich Kristian · CIK 0001920553 · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Indirect · See footnote.

Disclosed balance after: 2,764,746

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 10, 2026.

F2 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $20.00 to $20.25. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

F3 · ownership.nature: Represents the ordinary shares of the Issuer owned by JeruCON Beratungsgesellschaft mbH. Dr. Reich directly (whether through ownership or position) or indirectly through one or more intermediaries, may be deemed for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, to be the indirect beneficial owner of the ordinary shares owned by JeruCON Beratungsgesellschaft mbH.

SEC source: 0001213900-26-079376 · ownership.xml · nonDerivative · entry 1

Reich Kristian · CIK 0001920553 · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Indirect · See footnote.

Disclosed balance after: 2,808,446

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 10, 2026.

F2 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $20.00 to $20.04. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

F3 · ownership.nature: Represents the ordinary shares of the Issuer owned by JeruCON Beratungsgesellschaft mbH. Dr. Reich directly (whether through ownership or position) or indirectly through one or more intermediaries, may be deemed for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, to be the indirect beneficial owner of the ordinary shares owned by JeruCON Beratungsgesellschaft mbH.

SEC source: 0001213900-26-069753 · ownership.xml · nonDerivative · entry 3

Reich Kristian · CIK 0001920553 · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Indirect · See footnote.

Disclosed balance after: 2,824,551

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 10, 2026.

F5 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $18.915 to $19.97. Upon request by the staff of the Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

F3 · ownership.nature: Represents the ordinary shares of the Issuer owned by JeruCON Beratungsgesellschaft mbH. Dr. Reich directly (whether through ownership or position) or indirectly through one or more intermediaries, may be deemed for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, to be the indirect beneficial owner of the ordinary shares owned by JeruCON Beratungsgesellschaft mbH.

SEC source: 0001213900-26-069753 · ownership.xml · nonDerivative · entry 2

Reich Kristian · CIK 0001920553 · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Indirect · See footnote.

Disclosed balance after: 2,874,551

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 10, 2026.

F4 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $18.235 to $19.33. Upon request by the staff of the Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

F3 · ownership.nature: Represents the ordinary shares of the Issuer owned by JeruCON Beratungsgesellschaft mbH. Dr. Reich directly (whether through ownership or position) or indirectly through one or more intermediaries, may be deemed for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, to be the indirect beneficial owner of the ordinary shares owned by JeruCON Beratungsgesellschaft mbH.

SEC source: 0001213900-26-069753 · ownership.xml · nonDerivative · entry 1

Reich Kristian · CIK 0001920553 · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Indirect · See footnote.

Disclosed balance after: 2,924,551

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 10, 2026.

F2 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $18.66 to $19.12. Upon request by the staff of the U.S. Securities and Exchange Commission (the "Commission"), the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

F3 · ownership.nature: Represents the ordinary shares of the Issuer owned by JeruCON Beratungsgesellschaft mbH. Dr. Reich directly (whether through ownership or position) or indirectly through one or more intermediaries, may be deemed for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, to be the indirect beneficial owner of the ordinary shares owned by JeruCON Beratungsgesellschaft mbH.

SEC source: 0001213900-26-002905 · ownership.xml · derivative · entry 1

Reich Kristian · CIK 0001920553 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 520,342

Underlying: Class A ordinary shares, par value $0.0001 per share · 520,342 shares

Expires 2036-01-07

F1 · derivative.exercise_date: This option represents a right to purchase a total of 520,342 of the Issuer's Class A ordinary shares, vesting in four equal annual installments on January 7, 2027, 2028, 2029 and 2030, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date.

SEC source: 0001213900-25-124516 · ownership.xml · derivative · entry 4

Reich Kristian · CIK 0001920553 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A ordinary shares, par value $0.0001 per share · 35,389 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · security: 10,000 of the common shares of MoonLake AG held by the holder (the "second leaver shares") are subject to a reverse vesting condition, such that 25% vested on January 18, 2023 and 75% vest on the 18th of each month at a rate of 2.08%, and they will be fully vested on January 18, 2026 (the "second vesting period"). Upon the occurrence of any transfer of MoonLake AG shares in one or a series of related transactions that results in the proposed acquiror holding directly, or indirectly through one or more intermediaries, more than 50% of the then issued share capital of MoonLake AG, the unvested second leaver shares will fully vest.

F4 · security: (continued from footnote 3) If, before the end of the second vesting period the employment relationship of the holder is terminated (a) for any reason other than for cause, MoonLake AG or any third party designated by it, shall have an option to purchase all or a pro rata portion of the unvested second leaver shares at nominal value of CHF 0.10 per share or (b) for cause, MoonLake AG or any third party designated by it, shall have an option to purchase all or a pro rata portion of the second leaver shares at nominal value of CHF 0.10 per share. In connection with any such purchase of such second leaver shares, the corresponding Class C ordinary shares of the Issuer will also be transferred to the purchaser.

F2 · derivative.exercise_price: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

F1 · kind: On December 19, 2025, the Reporting Person exchanged 1,052 common shares of MoonLake Immunotherapeutics AG ("MoonLake AG") for 35,389 Class A ordinary shares of the Issuer. In connection with the exchange, 35,389 Class C ordinary shares of the Issuer were automatically cancelled by the Issuer for no consideration.

F2 · price: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

F2 · derivative.exercise_date: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

F2 · derivative.expiration_date: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

SEC source: 0001213900-25-124516 · ownership.xml · nonDerivative · entry 2

Reich Kristian · CIK 0001920553 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F2 · security: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

F3 · security: 10,000 of the common shares of MoonLake AG held by the holder (the "second leaver shares") are subject to a reverse vesting condition, such that 25% vested on January 18, 2023 and 75% vest on the 18th of each month at a rate of 2.08%, and they will be fully vested on January 18, 2026 (the "second vesting period"). Upon the occurrence of any transfer of MoonLake AG shares in one or a series of related transactions that results in the proposed acquiror holding directly, or indirectly through one or more intermediaries, more than 50% of the then issued share capital of MoonLake AG, the unvested second leaver shares will fully vest.

F4 · security: (continued from footnote 3) If, before the end of the second vesting period the employment relationship of the holder is terminated (a) for any reason other than for cause, MoonLake AG or any third party designated by it, shall have an option to purchase all or a pro rata portion of the unvested second leaver shares at nominal value of CHF 0.10 per share or (b) for cause, MoonLake AG or any third party designated by it, shall have an option to purchase all or a pro rata portion of the second leaver shares at nominal value of CHF 0.10 per share. In connection with any such purchase of such second leaver shares, the corresponding Class C ordinary shares of the Issuer will also be transferred to the purchaser.

F1 · kind: On December 19, 2025, the Reporting Person exchanged 1,052 common shares of MoonLake Immunotherapeutics AG ("MoonLake AG") for 35,389 Class A ordinary shares of the Issuer. In connection with the exchange, 35,389 Class C ordinary shares of the Issuer were automatically cancelled by the Issuer for no consideration.

F2 · price: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

SEC source: 0001213900-25-124516 · ownership.xml · nonDerivative · entry 1

Reich Kristian · CIK 0001920553 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,389

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: On December 19, 2025, the Reporting Person exchanged 1,052 common shares of MoonLake Immunotherapeutics AG ("MoonLake AG") for 35,389 Class A ordinary shares of the Issuer. In connection with the exchange, 35,389 Class C ordinary shares of the Issuer were automatically cancelled by the Issuer for no consideration.

F2 · price: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

SEC source: 0001213900-25-120105 · ownership.xml · nonDerivative · entry 2

Reich Kristian · CIK 0001920553 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F1 · acquired: Sales made pursuant to Rule 144 under the Securities Act of 1933, as amended, to cover tax liabilities of the Reporting Person and other expenses incurred related to the sales.

SEC source: 0001213900-25-120105 · ownership.xml · nonDerivative · entry 1

Reich Kristian · CIK 0001920553 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 72,908

F2 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $15.036949 to $15.101507. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

F1 · acquired: Sales made pursuant to Rule 144 under the Securities Act of 1933, as amended, to cover tax liabilities of the Reporting Person and other expenses incurred related to the sales.

SEC source: 0001213900-25-084492 · ownership.xml · nonDerivative · entry 2

Reich Kristian · CIK 0001920553 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,389

F2 · security: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

F3 · security: 10,000 of the common shares of MoonLake AG held by the holder (the "second leaver shares") are subject to a reverse vesting condition, such that 25% vested on January 18, 2023 and 75% vest on the 18th of each month at a rate of 2.08%, and they will be fully vested on January 18, 2026 (the "second vesting period"). Upon the occurrence of any transfer of MoonLake AG shares in one or a series of related transactions that results in the proposed acquiror holding directly, or indirectly through one or more intermediaries, more than 50% of the then issued share capital of MoonLake AG, the unvested second leaver shares will fully vest.

F4 · security: (continued from footnote 3) If, before the end of the second vesting period the employment relationship of the holder is terminated (a) for any reason other than for cause, MoonLake AG or any third party designated by it, shall have an option to purchase all or a pro rata portion of the unvested second leaver shares at nominal value of CHF 0.10 per share or (b) for cause, MoonLake AG or any third party designated by it, shall have an option to purchase all or a pro rata portion of the second leaver shares at nominal value of CHF 0.10 per share. In connection with any such purchase of such second leaver shares, the corresponding Class C ordinary shares of the Issuer will also be transferred to the purchaser.

F1 · kind: On September 2, 2025, the Reporting Person exchanged 1,456 common shares of MoonLake Immunotherapeutics AG ("MoonLake AG") for 48,978 Class A ordinary shares of the Issuer. In connection with the exchange, 48,978 Class C ordinary shares of the Issuer were automatically cancelled by the Issuer for no consideration.

F2 · price: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

SEC source: 0001213900-25-084492 · ownership.xml · nonDerivative · entry 1

Reich Kristian · CIK 0001920553 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 202,908

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: On September 2, 2025, the Reporting Person exchanged 1,456 common shares of MoonLake Immunotherapeutics AG ("MoonLake AG") for 48,978 Class A ordinary shares of the Issuer. In connection with the exchange, 48,978 Class C ordinary shares of the Issuer were automatically cancelled by the Issuer for no consideration.

F2 · price: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

SEC source: 0001213900-25-019673 · ownership.xml · derivative · entry 1

Reich Kristian · CIK 0001920553 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 139,273

Underlying: Class A ordinary shares, par value $0.0001 per share · 139,273 shares

Expires 2035-02-27

F1 · derivative.exercise_date: This option represents a right to purchase a total of 139,273 of the Issuer's Class A ordinary shares, vesting in four equal annual installments on February 27, 2026, 2027, 2028 and 2029, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date.

SEC source: 0001213900-25-005686 · ownership.xml · derivative · entry 4

Reich Kristian · CIK 0001920553 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,508

Underlying: Class A ordinary shares, par value $0.0001 per share · 111,949 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · security: 10,000 of the common shares of MoonLake AG held by the holder (the "second leaver shares") are subject to a reverse vesting condition, such that 25% vested on January 18, 2023 and 75% vest on the 18th of each month at a rate of 2.08%, and they will be fully vested on January 18, 2026 (the "second vesting period"). Upon the occurrence of any transfer of MoonLake AG shares in one or a series of related transactions that results in the proposed acquiror holding directly, or indirectly through one or more intermediaries, more than 50% of the then issued share capital of MoonLake AG, the unvested second leaver shares will fully vest.

F4 · security: (continued from footnote 3) If, before the end of the second vesting period the employment relationship of the holder is terminated (a) for any reason other than for cause, MoonLake AG or any third party designated by it, shall have an option to purchase all or a pro rata portion of the unvested second leaver shares at nominal value of CHF 0.10 per share or (b) for cause, MoonLake AG or any third party designated by it, shall have an option to purchase all or a pro rata portion of the second leaver shares at nominal value of CHF 0.10 per share. In connection with any such purchase of such second leaver shares, the corresponding Class C ordinary shares of the Issuer will also be transferred to the purchaser.

F2 · derivative.exercise_price: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

F1 · kind: On January 20, 2025, the Reporting Person exchanged 3,328 common shares of MoonLake Immunotherapeutics AG ("MoonLake AG") for 111,949 Class A ordinary shares of the Issuer. In connection with the exchange, 111,949 Class C ordinary shares of the Issuer were automatically cancelled by the Issuer for no consideration.

F2 · price: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

F2 · derivative.exercise_date: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

F2 · derivative.expiration_date: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

SEC source: 0001213900-25-005686 · ownership.xml · nonDerivative · entry 2

Reich Kristian · CIK 0001920553 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 84,367

F2 · security: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

F3 · security: 10,000 of the common shares of MoonLake AG held by the holder (the "second leaver shares") are subject to a reverse vesting condition, such that 25% vested on January 18, 2023 and 75% vest on the 18th of each month at a rate of 2.08%, and they will be fully vested on January 18, 2026 (the "second vesting period"). Upon the occurrence of any transfer of MoonLake AG shares in one or a series of related transactions that results in the proposed acquiror holding directly, or indirectly through one or more intermediaries, more than 50% of the then issued share capital of MoonLake AG, the unvested second leaver shares will fully vest.

F4 · security: (continued from footnote 3) If, before the end of the second vesting period the employment relationship of the holder is terminated (a) for any reason other than for cause, MoonLake AG or any third party designated by it, shall have an option to purchase all or a pro rata portion of the unvested second leaver shares at nominal value of CHF 0.10 per share or (b) for cause, MoonLake AG or any third party designated by it, shall have an option to purchase all or a pro rata portion of the second leaver shares at nominal value of CHF 0.10 per share. In connection with any such purchase of such second leaver shares, the corresponding Class C ordinary shares of the Issuer will also be transferred to the purchaser.

F1 · kind: On January 20, 2025, the Reporting Person exchanged 3,328 common shares of MoonLake Immunotherapeutics AG ("MoonLake AG") for 111,949 Class A ordinary shares of the Issuer. In connection with the exchange, 111,949 Class C ordinary shares of the Issuer were automatically cancelled by the Issuer for no consideration.

F2 · price: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

SEC source: 0001213900-25-005686 · ownership.xml · nonDerivative · entry 1

Reich Kristian · CIK 0001920553 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 153,930

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: On January 20, 2025, the Reporting Person exchanged 3,328 common shares of MoonLake Immunotherapeutics AG ("MoonLake AG") for 111,949 Class A ordinary shares of the Issuer. In connection with the exchange, 111,949 Class C ordinary shares of the Issuer were automatically cancelled by the Issuer for no consideration.

F2 · price: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

SEC source: 0001213900-25-084492 · ownership.xml · derivative · entry 4

Reich Kristian · CIK 0001920553 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,052

Underlying: Class A ordinary shares, par value $0.0001 per share · 48,978 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · security: 10,000 of the common shares of MoonLake AG held by the holder (the "second leaver shares") are subject to a reverse vesting condition, such that 25% vested on January 18, 2023 and 75% vest on the 18th of each month at a rate of 2.08%, and they will be fully vested on January 18, 2026 (the "second vesting period"). Upon the occurrence of any transfer of MoonLake AG shares in one or a series of related transactions that results in the proposed acquiror holding directly, or indirectly through one or more intermediaries, more than 50% of the then issued share capital of MoonLake AG, the unvested second leaver shares will fully vest.

F4 · security: (continued from footnote 3) If, before the end of the second vesting period the employment relationship of the holder is terminated (a) for any reason other than for cause, MoonLake AG or any third party designated by it, shall have an option to purchase all or a pro rata portion of the unvested second leaver shares at nominal value of CHF 0.10 per share or (b) for cause, MoonLake AG or any third party designated by it, shall have an option to purchase all or a pro rata portion of the second leaver shares at nominal value of CHF 0.10 per share. In connection with any such purchase of such second leaver shares, the corresponding Class C ordinary shares of the Issuer will also be transferred to the purchaser.

F2 · derivative.exercise_price: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

F1 · kind: On September 2, 2025, the Reporting Person exchanged 1,456 common shares of MoonLake Immunotherapeutics AG ("MoonLake AG") for 48,978 Class A ordinary shares of the Issuer. In connection with the exchange, 48,978 Class C ordinary shares of the Issuer were automatically cancelled by the Issuer for no consideration.

F2 · price: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

F2 · derivative.exercise_date: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

F2 · derivative.expiration_date: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

SEC source: 0001213900-24-018671 · ownership.xml · nonDerivative · entry 4

Reich Kristian · CIK 0001920553 · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 41,981

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on October 16, 2023.

SEC source: 0001213900-24-018671 · ownership.xml · nonDerivative · entry 3

Reich Kristian · CIK 0001920553 · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Indirect · See footnote.

Disclosed balance after: 2,925,573

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on October 16, 2023.

F2 · ownership.nature: Represents the ordinary shares of the Issuer owned by JeruCON Beratungsgesellschaft mbH. Dr. Reich directly (whether through ownership or position) or indirectly through one or more intermediaries, may be deemed for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, to be the indirect beneficial owner of the ordinary shares owned by JeruCON Beratungsgesellschaft mbH.

SEC source: 0001213900-24-018671 · ownership.xml · nonDerivative · entry 2

Reich Kristian · CIK 0001920553 · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 70,071

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on October 16, 2023.

SEC source: 0001213900-24-018671 · ownership.xml · nonDerivative · entry 1

Reich Kristian · CIK 0001920553 · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Indirect · See footnote.

Disclosed balance after: 2,957,483

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on October 16, 2023.

F2 · ownership.nature: Represents the ordinary shares of the Issuer owned by JeruCON Beratungsgesellschaft mbH. Dr. Reich directly (whether through ownership or position) or indirectly through one or more intermediaries, may be deemed for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, to be the indirect beneficial owner of the ordinary shares owned by JeruCON Beratungsgesellschaft mbH.

SEC source: 0001213900-24-016240 · ownership.xml · nonDerivative · entry 4

Reich Kristian · CIK 0001920553 · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 99,502

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on October 16, 2023.

F6 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $55.15 to $55.33. Upon request by the staff of the Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

SEC source: 0001213900-24-016240 · ownership.xml · nonDerivative · entry 3

Reich Kristian · CIK 0001920553 · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Indirect · See footnote.

Disclosed balance after: 2,986,974

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on October 16, 2023.

F5 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $55.225 to $55.33. Upon request by the staff of the Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

F3 · ownership.nature: Represents the ordinary shares of the Issuer owned by JeruCON Beratungsgesellschaft mbH. Dr. Reich directly (whether through ownership or position) or indirectly through one or more intermediaries, may be deemed for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, to be the indirect beneficial owner of the ordinary shares owned by JeruCON Beratungsgesellschaft mbH.

SEC source: 0001213900-24-016240 · ownership.xml · nonDerivative · entry 2

Reich Kristian · CIK 0001920553 · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 100,071

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on October 16, 2023.

F4 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $55.14 to $59.09. Upon request by the staff of the Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

SEC source: 0001213900-24-016240 · ownership.xml · nonDerivative · entry 1

Reich Kristian · CIK 0001920553 · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Indirect · See footnote.

Disclosed balance after: 2,987,483

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on October 16, 2023.

F2 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $55.06 to $59.09. Upon request by the staff of the U.S. Securities and Exchange Commission (the "Commission"), the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

F3 · ownership.nature: Represents the ordinary shares of the Issuer owned by JeruCON Beratungsgesellschaft mbH. Dr. Reich directly (whether through ownership or position) or indirectly through one or more intermediaries, may be deemed for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, to be the indirect beneficial owner of the ordinary shares owned by JeruCON Beratungsgesellschaft mbH.

SEC source: 0001213900-24-014996 · ownership.xml · nonDerivative · entry 6

Reich Kristian · CIK 0001920553 · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 110,071

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on October 16, 2023.

F8 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $59.34 to $61.17. Upon request by the staff of the Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

SEC source: 0001213900-24-014996 · ownership.xml · nonDerivative · entry 5

Reich Kristian · CIK 0001920553 · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Indirect · See footnote.

Disclosed balance after: 2,997,483

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on October 16, 2023.

F7 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $59.34 to $61.17. Upon request by the staff of the Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

F3 · ownership.nature: Represents the ordinary shares of the Issuer owned by JeruCON Beratungsgesellschaft mbH. Dr. Reich directly (whether through ownership or position) or indirectly through one or more intermediaries, may be deemed for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, to be the indirect beneficial owner of the ordinary shares owned by JeruCON Beratungsgesellschaft mbH.

SEC source: 0001213900-24-014996 · ownership.xml · nonDerivative · entry 4

Reich Kristian · CIK 0001920553 · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 120,071

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on October 16, 2023.

F6 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $58.18 to $63.95. Upon request by the staff of the Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

SEC source: 0001213900-24-014996 · ownership.xml · nonDerivative · entry 3

Reich Kristian · CIK 0001920553 · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Indirect · See footnote.

Disclosed balance after: 3,007,483

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on October 16, 2023.

F5 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $58.10 to $63.95. Upon request by the staff of the Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

F3 · ownership.nature: Represents the ordinary shares of the Issuer owned by JeruCON Beratungsgesellschaft mbH. Dr. Reich directly (whether through ownership or position) or indirectly through one or more intermediaries, may be deemed for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, to be the indirect beneficial owner of the ordinary shares owned by JeruCON Beratungsgesellschaft mbH.

SEC source: 0001213900-24-014996 · ownership.xml · nonDerivative · entry 2

Reich Kristian · CIK 0001920553 · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 130,071

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on October 16, 2023.

F4 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $61.82 to $63.01. Upon request by the staff of the Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

SEC source: 0001213900-24-014996 · ownership.xml · nonDerivative · entry 1

Reich Kristian · CIK 0001920553 · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Indirect · See footnote.

Disclosed balance after: 3,017,483

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on October 16, 2023.

F2 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $61.82 to $63.01. Upon request by the staff of the U.S. Securities and Exchange Commission (the "Commission"), the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

F3 · ownership.nature: Represents the ordinary shares of the Issuer owned by JeruCON Beratungsgesellschaft mbH. Dr. Reich directly (whether through ownership or position) or indirectly through one or more intermediaries, may be deemed for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, to be the indirect beneficial owner of the ordinary shares owned by JeruCON Beratungsgesellschaft mbH.

SEC source: 0001013762-23-001295 · ownership.xml · derivative · entry 6

Reich Kristian · CIK 0001920553 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,836

Underlying: Class A ordinary shares, par value $0.0001 per share · 41,981 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · security: 10,000 of the common shares of MoonLake AG held by the holder (the "second leaver shares") are subject to a reverse vesting condition, such that 25% vested on January 18, 2023 and 75% vest on the 18th of each month at a rate of 2.08%, and they will be fully vested on January 18, 2026 (the "second vesting period"). Upon the occurrence of any transfer of MoonLake AG shares in one or a series of related transactions that results in the proposed acquiror holding directly, or indirectly through one or more intermediaries, more than 50% of the then issued share capital of MoonLake AG (a "Change of Control"), the unvested second leaver shares will fully vest.

F6 · security: (continued from footnote 6) If, before the end of the second vesting period the employment relationship of the holder is terminated (a) for any reason other than for cause, MoonLake AG or any third party designated by it, shall have an option to purchase all or a pro rata portion of the unvested second leaver shares at nominal value of CHF 0.10 per share or (b) for cause, MoonLake AG or any third party designated by it, shall have an option to purchase all or a pro rata portion of the second leaver shares at nominal value of CHF 0.10 per share. In connection with any such purchase of such second leaver shares, the corresponding Class C ordinary shares of the Issuer will also be transferred to the purchaser.

F2 · derivative.exercise_price: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

F4 · kind: On October 1, 2023, the Reporting Person exchanged 1,248 common shares of MoonLake AG for 41,981 shares of Class A ordinary shares. In connection with the exchange, 41,981 shares of Class C ordinary shares were automatically cancelled by the Issuer for no consideration.

F2 · price: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

F2 · derivative.exercise_date: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

F2 · derivative.expiration_date: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

SEC source: 0001013762-23-001295 · ownership.xml · derivative · entry 5

Reich Kristian · CIK 0001920553 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote.

Disclosed balance after: 0

Underlying: Class A ordinary shares, par value $0.0001 per share · 2,527,477 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

F1 · kind: On October 1, 2023, the Reporting Person exchanged 75,136 common shares of MoonLake Immunotherapeutics AG ("MoonLake AG") for 2,527,477 Class A ordinary shares of the Issuer. In connection with the exchange, 2,527,477 Class C ordinary shares of the Issuer were automatically cancelled by the Issuer for no consideration.

F2 · price: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

F2 · derivative.exercise_date: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

F2 · derivative.expiration_date: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

F3 · ownership.nature: Represents the ordinary shares of the Issuer owned by JeruCon Beratungsgesellschaft mbH. Dr. Reich directly (whether through ownership or position) or indirectly through one or more intermediaries, may be deemed for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, to be the indirect beneficial owner of the ordinary shares (and the corresponding common shares of MoonLake AG) owned by JeruCon Beratungsgesellschaft mbH.

SEC source: 0001013762-23-001295 · ownership.xml · nonDerivative · entry 4

Reich Kristian · CIK 0001920553 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 196,316

F2 · security: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

F5 · security: 10,000 of the common shares of MoonLake AG held by the holder (the "second leaver shares") are subject to a reverse vesting condition, such that 25% vested on January 18, 2023 and 75% vest on the 18th of each month at a rate of 2.08%, and they will be fully vested on January 18, 2026 (the "second vesting period"). Upon the occurrence of any transfer of MoonLake AG shares in one or a series of related transactions that results in the proposed acquiror holding directly, or indirectly through one or more intermediaries, more than 50% of the then issued share capital of MoonLake AG (a "Change of Control"), the unvested second leaver shares will fully vest.

F6 · security: (continued from footnote 6) If, before the end of the second vesting period the employment relationship of the holder is terminated (a) for any reason other than for cause, MoonLake AG or any third party designated by it, shall have an option to purchase all or a pro rata portion of the unvested second leaver shares at nominal value of CHF 0.10 per share or (b) for cause, MoonLake AG or any third party designated by it, shall have an option to purchase all or a pro rata portion of the second leaver shares at nominal value of CHF 0.10 per share. In connection with any such purchase of such second leaver shares, the corresponding Class C ordinary shares of the Issuer will also be transferred to the purchaser.

F4 · kind: On October 1, 2023, the Reporting Person exchanged 1,248 common shares of MoonLake AG for 41,981 shares of Class A ordinary shares. In connection with the exchange, 41,981 shares of Class C ordinary shares were automatically cancelled by the Issuer for no consideration.

F2 · price: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

SEC source: 0001013762-23-001295 · ownership.xml · nonDerivative · entry 3

Reich Kristian · CIK 0001920553 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 140,071

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · kind: On October 1, 2023, the Reporting Person exchanged 1,248 common shares of MoonLake AG for 41,981 shares of Class A ordinary shares. In connection with the exchange, 41,981 shares of Class C ordinary shares were automatically cancelled by the Issuer for no consideration.

F2 · price: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

SEC source: 0001013762-23-001295 · ownership.xml · nonDerivative · entry 2

Reich Kristian · CIK 0001920553 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote.

Disclosed balance after: 0

F2 · security: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

F1 · kind: On October 1, 2023, the Reporting Person exchanged 75,136 common shares of MoonLake Immunotherapeutics AG ("MoonLake AG") for 2,527,477 Class A ordinary shares of the Issuer. In connection with the exchange, 2,527,477 Class C ordinary shares of the Issuer were automatically cancelled by the Issuer for no consideration.

F2 · price: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

F3 · ownership.nature: Represents the ordinary shares of the Issuer owned by JeruCon Beratungsgesellschaft mbH. Dr. Reich directly (whether through ownership or position) or indirectly through one or more intermediaries, may be deemed for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, to be the indirect beneficial owner of the ordinary shares (and the corresponding common shares of MoonLake AG) owned by JeruCon Beratungsgesellschaft mbH.

SEC source: 0001013762-23-001295 · ownership.xml · nonDerivative · entry 1

Reich Kristian · CIK 0001920553 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote.

Disclosed balance after: 3,027,483

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: On October 1, 2023, the Reporting Person exchanged 75,136 common shares of MoonLake Immunotherapeutics AG ("MoonLake AG") for 2,527,477 Class A ordinary shares of the Issuer. In connection with the exchange, 2,527,477 Class C ordinary shares of the Issuer were automatically cancelled by the Issuer for no consideration.

F2 · price: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

F3 · ownership.nature: Represents the ordinary shares of the Issuer owned by JeruCon Beratungsgesellschaft mbH. Dr. Reich directly (whether through ownership or position) or indirectly through one or more intermediaries, may be deemed for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, to be the indirect beneficial owner of the ordinary shares (and the corresponding common shares of MoonLake AG) owned by JeruCon Beratungsgesellschaft mbH.

SEC source: 0001213900-23-028293 · ownership.xml · derivative · entry 6

Reich Kristian · CIK 0001920553 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,084

Underlying: Class A ordinary shares, par value $0.0001 per share · 98,090 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · security: 10,000 of the common shares of MoonLake AG held by the holder (the "second leaver shares") are subject to a reverse vesting condition, such that 25% vested on January 18, 2023 and 75% vest on the 18th of each month at a rate of 2.08%, and they will be fully vested on January 18, 2026 (the "second vesting period"). Upon the occurrence of any transfer of MoonLake AG shares in one or a series of related transactions that results in the proposed acquiror holding directly, or indirectly through one or more intermediaries, more than 50% of the then issued share capital of MoonLake AG (a "Change of Control"), the unvested second leaver shares will fully vest the earlier of (a) 12 months after the occurrence of a Change of Control or (b) the date after the occurrence of the Change of Control on which the holder's employment relationship is terminated.

F7 · security: (continued from footnote 6) If, before the end of the second vesting period the employment relationship of the holder is terminated (a) for any reason other than for cause, MoonLake AG or any third party designated by it, shall have an option to purchase all or a pro rata portion of the unvested second leaver shares at nominal value of CHF 0.10 per share or (b) for cause, MoonLake AG or any third party designated by it, shall have an option to purchase all or a pro rata portion of the second leaver shares at nominal value of CHF 0.10 per share. In connection with any such purchase of such second leaver shares, the corresponding Class C ordinary shares of the Issuer will also be transferred to the purchaser.

F2 · derivative.exercise_price: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

F5 · kind: On April 5, 2023, the Reporting Person exchanged 2,916 common shares of MoonLake AG for 98,090 shares of Class A ordinary shares. In connection with the exchange, 98,090 shares of Class C ordinary shares were automatically cancelled by the Issuer for no consideration.

F2 · price: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

F2 · derivative.exercise_date: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

F2 · derivative.expiration_date: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

SEC source: 0001213900-23-028293 · ownership.xml · derivative · entry 5

Reich Kristian · CIK 0001920553 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote.

Disclosed balance after: 75,136

Underlying: Class A ordinary shares, par value $0.0001 per share · 500,006 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · security: 53,625 of the common shares of MoonLake AG held by the holder (the "initial leaver shares") are subject to a reverse vesting condition, such that 4,125 initial leaver shares vest on the 28th of each month, and they will be fully vested on April 28, 2023 (the "initial vesting period"). If, before the end of the initial vesting period (a) the employment relationship of the holder is terminated for any reason other than for cause, the vesting of all unvested initial leaver shares shall accelerate as of the effective date of termination or (b) the employment relationship of the holder is terminated for cause, MoonLake AG in first priority, and the Issuer in second priority shall have an option to purchase all or a pro rata portion of the unvested initial leaver shares at nominal value of CHF 0.10 per share. In connection with any such purchase of such initial leaver shares, the corresponding Class C ordinary shares of the Issuer will also be transferred to the purchaser.

F2 · derivative.exercise_price: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

F1 · kind: On April 5, 2023, the Reporting Person exchanged 14,864 common shares of MoonLake Immunotherapeutics AG ("MoonLake AG") for 500,006 Class A ordinary shares of the Issuer. In connection with the exchange, 500,006 Class C ordinary shares of the Issuer were automatically cancelled by the Issuer for no consideration.

F2 · price: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

F2 · derivative.exercise_date: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

F2 · derivative.expiration_date: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

F3 · ownership.nature: Represents the ordinary shares of the Issuer owned by JeruCon Beratungsgesellschaft mbH. Dr. Reich directly (whether through ownership or position) or indirectly through one or more intermediaries, may be deemed for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, to be the indirect beneficial owner of the ordinary shares (and the corresponding common shares of MoonLake AG) owned by JeruCon Beratungsgesellschaft mbH.

SEC source: 0001213900-23-028293 · ownership.xml · nonDerivative · entry 4

Reich Kristian · CIK 0001920553 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 238,297

F2 · security: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

F6 · security: 10,000 of the common shares of MoonLake AG held by the holder (the "second leaver shares") are subject to a reverse vesting condition, such that 25% vested on January 18, 2023 and 75% vest on the 18th of each month at a rate of 2.08%, and they will be fully vested on January 18, 2026 (the "second vesting period"). Upon the occurrence of any transfer of MoonLake AG shares in one or a series of related transactions that results in the proposed acquiror holding directly, or indirectly through one or more intermediaries, more than 50% of the then issued share capital of MoonLake AG (a "Change of Control"), the unvested second leaver shares will fully vest the earlier of (a) 12 months after the occurrence of a Change of Control or (b) the date after the occurrence of the Change of Control on which the holder's employment relationship is terminated.

F7 · security: (continued from footnote 6) If, before the end of the second vesting period the employment relationship of the holder is terminated (a) for any reason other than for cause, MoonLake AG or any third party designated by it, shall have an option to purchase all or a pro rata portion of the unvested second leaver shares at nominal value of CHF 0.10 per share or (b) for cause, MoonLake AG or any third party designated by it, shall have an option to purchase all or a pro rata portion of the second leaver shares at nominal value of CHF 0.10 per share. In connection with any such purchase of such second leaver shares, the corresponding Class C ordinary shares of the Issuer will also be transferred to the purchaser.

F5 · kind: On April 5, 2023, the Reporting Person exchanged 2,916 common shares of MoonLake AG for 98,090 shares of Class A ordinary shares. In connection with the exchange, 98,090 shares of Class C ordinary shares were automatically cancelled by the Issuer for no consideration.

F2 · price: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

SEC source: 0001213900-23-028293 · ownership.xml · nonDerivative · entry 3

Reich Kristian · CIK 0001920553 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 98,090

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · kind: On April 5, 2023, the Reporting Person exchanged 2,916 common shares of MoonLake AG for 98,090 shares of Class A ordinary shares. In connection with the exchange, 98,090 shares of Class C ordinary shares were automatically cancelled by the Issuer for no consideration.

F2 · price: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

SEC source: 0001213900-23-028293 · ownership.xml · nonDerivative · entry 2

Reich Kristian · CIK 0001920553 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote.

Disclosed balance after: 2,527,477

F2 · security: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

F4 · security: 53,625 of the common shares of MoonLake AG held by the holder (the "initial leaver shares") are subject to a reverse vesting condition, such that 4,125 initial leaver shares vest on the 28th of each month, and they will be fully vested on April 28, 2023 (the "initial vesting period"). If, before the end of the initial vesting period (a) the employment relationship of the holder is terminated for any reason other than for cause, the vesting of all unvested initial leaver shares shall accelerate as of the effective date of termination or (b) the employment relationship of the holder is terminated for cause, MoonLake AG in first priority, and the Issuer in second priority shall have an option to purchase all or a pro rata portion of the unvested initial leaver shares at nominal value of CHF 0.10 per share. In connection with any such purchase of such initial leaver shares, the corresponding Class C ordinary shares of the Issuer will also be transferred to the purchaser.

F1 · kind: On April 5, 2023, the Reporting Person exchanged 14,864 common shares of MoonLake Immunotherapeutics AG ("MoonLake AG") for 500,006 Class A ordinary shares of the Issuer. In connection with the exchange, 500,006 Class C ordinary shares of the Issuer were automatically cancelled by the Issuer for no consideration.

F2 · price: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

F3 · ownership.nature: Represents the ordinary shares of the Issuer owned by JeruCon Beratungsgesellschaft mbH. Dr. Reich directly (whether through ownership or position) or indirectly through one or more intermediaries, may be deemed for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, to be the indirect beneficial owner of the ordinary shares (and the corresponding common shares of MoonLake AG) owned by JeruCon Beratungsgesellschaft mbH.

SEC source: 0001213900-23-028293 · ownership.xml · nonDerivative · entry 1

Reich Kristian · CIK 0001920553 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote.

Disclosed balance after: 500,006

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: On April 5, 2023, the Reporting Person exchanged 14,864 common shares of MoonLake Immunotherapeutics AG ("MoonLake AG") for 500,006 Class A ordinary shares of the Issuer. In connection with the exchange, 500,006 Class C ordinary shares of the Issuer were automatically cancelled by the Issuer for no consideration.

F2 · price: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

F3 · ownership.nature: Represents the ordinary shares of the Issuer owned by JeruCon Beratungsgesellschaft mbH. Dr. Reich directly (whether through ownership or position) or indirectly through one or more intermediaries, may be deemed for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, to be the indirect beneficial owner of the ordinary shares (and the corresponding common shares of MoonLake AG) owned by JeruCon Beratungsgesellschaft mbH.